WO2009051213A1 - 白斑治療剤および色素沈着促進方法 - Google Patents

白斑治療剤および色素沈着促進方法 Download PDF

Info

Publication number
WO2009051213A1
WO2009051213A1 PCT/JP2008/068828 JP2008068828W WO2009051213A1 WO 2009051213 A1 WO2009051213 A1 WO 2009051213A1 JP 2008068828 W JP2008068828 W JP 2008068828W WO 2009051213 A1 WO2009051213 A1 WO 2009051213A1
Authority
WO
WIPO (PCT)
Prior art keywords
leukoderma
ulcer
therapeutic agent
pigmentation
epidermis
Prior art date
Application number
PCT/JP2008/068828
Other languages
English (en)
French (fr)
Inventor
Kunihiko Tamaki
Kanako Kikuchi
Mayumi Komine
Seiki Fujimoto
Original Assignee
The University Of Tokyo
Maruho Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Tokyo, Maruho Co., Ltd. filed Critical The University Of Tokyo
Priority to CA2700729A priority Critical patent/CA2700729A1/en
Priority to JP2009538158A priority patent/JPWO2009051213A1/ja
Priority to US12/738,151 priority patent/US20100222275A1/en
Priority to EP08838612A priority patent/EP2198887A4/en
Publication of WO2009051213A1 publication Critical patent/WO2009051213A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Abstract

　ひ薄化している白斑部位の表皮を肥厚させることにより色素沈着を促進して、白斑を治療することができる医薬品および表皮を肥厚させることにより色素沈着を促進する方法を提供することである。 　表皮肥厚作用を有する化合物、例えば、熱傷潰瘍、下腿潰瘍、糖尿病潰瘍、もしくは術後潰瘍などの皮膚潰瘍の治療に用いられている皮膚潰瘍治療剤、または褥瘡治療剤を用いることにより、白斑を治療することができる。
PCT/JP2008/068828 2007-10-19 2008-10-17 白斑治療剤および色素沈着促進方法 WO2009051213A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2700729A CA2700729A1 (en) 2007-10-19 2008-10-17 Therapeutic agent for vitiligo and method of accelerating pigmentation
JP2009538158A JPWO2009051213A1 (ja) 2007-10-19 2008-10-17 白斑治療剤および色素沈着促進方法
US12/738,151 US20100222275A1 (en) 2007-10-19 2008-10-17 Therapeutic agent for vitiligo and method of accelerating pigmentation
EP08838612A EP2198887A4 (en) 2007-10-19 2008-10-17 THERAPEUTIC AGENT FOR LEUCODERM AND METHOD FOR ACCELERATING PIGMENTATION

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007273181 2007-10-19
JP2007-273181 2007-10-19
JP2008097207 2008-04-03
JP2008-097207 2008-04-03

Publications (1)

Publication Number Publication Date
WO2009051213A1 true WO2009051213A1 (ja) 2009-04-23

Family

ID=40567474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/068828 WO2009051213A1 (ja) 2007-10-19 2008-10-17 白斑治療剤および色素沈着促進方法

Country Status (5)

Country Link
US (1) US20100222275A1 (ja)
EP (2) EP2491928A2 (ja)
JP (1) JPWO2009051213A1 (ja)
CA (1) CA2700729A1 (ja)
WO (1) WO2009051213A1 (ja)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63107935A (ja) * 1986-06-16 1988-05-12 Dai Ichi Seiyaku Co Ltd 皮膚潰瘍治療剤
JP2002520275A (ja) * 1998-07-13 2002-07-09 ビー・テイー・ジー・インターナシヨナル・リミテツド 皮膚病の治療
WO2003035662A1 (en) 2001-10-25 2003-05-01 King Pharmaceuticals Research & Development, Inc. Synthesis of 2-aralkoxy adenosines and 2-alkoxyadenosines
JP2003520572A (ja) * 1999-07-02 2003-07-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ケラチノサイト増殖因子−２

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094771B1 (en) * 1982-05-15 1987-08-05 Beecham Group Plc Skin treatment compositions
FR2654935B1 (fr) * 1989-11-28 1994-07-01 Lvmh Rech Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
US5698184A (en) * 1996-08-23 1997-12-16 Skin Biology, Inc. Compositions and methods for skin tanning and protection
JP2001526215A (ja) * 1997-12-19 2001-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｒａｍｂａおよびトコフェロールの組み合わせ剤
GB0020351D0 (en) * 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
US7368131B2 (en) * 2003-02-27 2008-05-06 Supernatural Health, Inc. Method and composition for treating hypopigmentation of the hair and skin
US20070270472A1 (en) * 2004-07-09 2007-11-22 Raphael Beumer Amino, Amino Acid or Peptide Conjugates of Retinoic Acid
HU227723B1 (en) * 2004-07-09 2012-01-30 Nagy Norbert Dr Autologous keratinocytes, melanocytes and fibroblast culturing technique and serum-free medium for use in human therapy
KR100798853B1 (ko) 2005-02-15 2008-01-28 (주)한국스티펠 레티노이드를 유효성분으로 하는 백반증 예방 및 치료용 약학적 조성물
FR2903702B1 (fr) * 2006-07-13 2012-10-19 Oreal Equivalent d'epiderme capable de se pigmenter obtenu a partir de cellules de la matrice, procede de preparation et utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63107935A (ja) * 1986-06-16 1988-05-12 Dai Ichi Seiyaku Co Ltd 皮膚潰瘍治療剤
JP2002520275A (ja) * 1998-07-13 2002-07-09 ビー・テイー・ジー・インターナシヨナル・リミテツド 皮膚病の治療
JP2003520572A (ja) * 1999-07-02 2003-07-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ケラチノサイト増殖因子−２
WO2003035662A1 (en) 2001-10-25 2003-05-01 King Pharmaceuticals Research & Development, Inc. Synthesis of 2-aralkoxy adenosines and 2-alkoxyadenosines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HALABAN, R. ET AL.: "Basic fibroblast growth factor from human keratinocytesis a natural mitogen for melanocytes", J CELL BIOL, vol. 107, no. 4, 1988, pages 1611 - 1619, XP008132393 *
J. INVEST. DERMATOL., vol. 124, 2005, pages 976 - 983
MIZUSHIMA Y. ET AL.: "Konnichi no Chiryoyaku (1999 Nenban)", 5 June 1999, KABUSHIKI KAISHA NANKODO, pages: 233, 859 *
See also references of EP2198887A4

Also Published As

Publication number Publication date
CA2700729A1 (en) 2009-04-23
EP2198887A4 (en) 2011-11-30
JPWO2009051213A1 (ja) 2011-03-03
EP2198887A1 (en) 2010-06-23
EP2491928A2 (en) 2012-08-29
US20100222275A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
WO2007089454A3 (en) Methods for enhancing skin treatments
WO2006125092A3 (en) Treatment device and method for treating skin lesions through application of heat
WO2009075879A8 (en) Systems, apparatus, methods and procedures for the noninvasive treatment of tissue using microwave energy
WO2012078561A3 (en) A drape having microstrain inducing projections for treating a wound site
WO2010017556A8 (en) Method and apparatus for fractional deformation and treatment of cutaneous and subcutaneous tissue
WO2009158125A8 (en) Reduced-pressure, linear-wound treatment systems
WO2007100675A3 (en) Collagenase for treating cellulite
TW200602030A (en) Use of loteprednol etabonate for the treatment of dry eye
WO2010135056A3 (en) Phimosis treatment device and method
WO2011159118A3 (ko) 레이저를 이용한 흉터 및 피부질환 치료 시스템 및 그 방법
WO2007098114A3 (en) Clotting and healing compositions containing keratin biomaterials
WO2008130607A3 (en) Wound healing compositions containing keratin biomaterials
WO2007126999A3 (en) System and method for microablation of tissue
WO2009022338A3 (en) Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
WO2007105203A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
WO2011130389A3 (en) System and method for microablation of tissue
WO2007023072A3 (en) Use of ambroxol for the treatment of rhinovirus infections
WO2006136428A3 (en) Method and composition to treat skin ulcers
WO2010151778A3 (en) Topical compositions and methods for wound care
WO2008046407A3 (de) Verwendung von deuteriumdioxid zur behandlung von hyperproliferativen erkrankungen der haut
WO2010045575A3 (en) Compositions and methods for treatment of renin-angiotensin aldosterone system (raas)-related disorders
WO2007100590A3 (en) Methods for treating cellulite
WO2006047625A3 (en) Method to promote wound healing
WO2009051213A1 (ja) 白斑治療剤および色素沈着促進方法
WO2003034999A3 (en) Medication and method for remediating existing scars through transdermal topical delivery of calcium channel blockers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08838612

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2700729

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008838612

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009538158

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12738151

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE